Clinical Research On Chronic Severe Hepatitis Of Danhuangfang

Objective:To observe the treatment and security , pathogenesis of Danhu-angfang on chronic severe hepatitis. Methods:Choose the patients (with a total of 48 cases) treated from August 2007 to February 2009 and diagnosed as chronic severe hepatitis by wuhan medical treatment center.Forty eight cases were randomly divided into two groups, each 24, one for treatment and the other for control in clinical trial. The control group were treated by protecting liver cells, debasing the level of transaminase and bilirubin, promoting the regenesis of liver cells, keeping the balance of water, salt and electrolyte, plasma exchange and other integrated supporting treatment and anti-virus therapy for the symptom in western medicine. In the base of the treatments which were used in the control group, the cases in the therapy group taked Danhuangfang of one dosage decocting with water at twice per day.The control group and the therapy group were treated for one month respectively. To observe the changes of clinical syndrome, traditional Chinese medicine syndrome integral, live function (ALT,AST,TBiL,AMM,ALB,PTA)and B supersonic wave on liver and spleen, and secure index (concluding blood,urine,stool routine and renal function,ECG), complications and prognosis in the two groups after the treatments and detected the change of ET,TNF-αbefore and after the treatment.After the clinical trial, the data was analyzed, the measuring materials and the grade materials were examined with Chi-square test, T-test and Ridit respectively. All data was analyzed by SPSS.Results:1.The curative effect of colligation:The treated group: clinical obvious effective rate is 20.8%, total effective rate is 87. 5%;The control group: obvious effective rate is 12. 5%, total effective rate is 62.5%;The effective rate of treated group was better than that of the control group, and there are obvious statistics difference between two groups (P<0.05).2.The curative effect of traditional Chinese medicine syndrome:The treated groups: obvious effective rate is 29.2%, total progressive rate is 91.6%;The control group: obvious effective rate is 12.5%, total effective rate is 66.7%;The effective rate of treated group was better than that of the control group, and there are statistics difference between two groups (P<0. 05). 3.The curative effect of liver function (ALT,AST,TBi1,AMM,ALB and PTA):(1) After the treatment, the effective rate of ALT and AST in the two group were better than before(P<0. 05), the control group is better than the treated group but there is no statistics difference between two groups(P>0. 05).(2) After the treatment, the effective rate of TBiL and AMM in the two group were better than before (P<0. 05), the control group is better than the treated group and there are statistics differences between two groups (P<0. 05).(3) After the treatment, the effective rate of ALB in the two group were better than before(P<0. 05), but there isn't any statistics difference between two groups (P>0. 05) , the effective rate of PTA in the two group were better than before(P<0. 05), the control group is better than the treated group ,and there are statistics differences between two groups (P<0. 05).4. The curative effect of ET and TNF-α: After the treatment, the effective rate of ET and TNF-αin the two groups were better than before(P<0. 05), the control group is better than the treated group and there are statistics differences between two groups (P<0. 05).5.There is no statistics difference on B supersonic wave between two groups (P>0. 05).6. The safety index: the two groups were not discovered adverse reaction and harmful effect on cases. There was not abnormal change on blood,urine,stool routine and renal function,ECG of cases.Conclution: Danhuangfang can improve clinical syndrome, live function (ALT,AST,TBiL,AMM,ALB,PTA)of chronic severe hepatitis, The effect in the group of dan huang fang was better than the pure western medicine group, and obviously reduced the ET and TNF-α. Danhuangfang have not the serious side effects in this clinical research.